Budapest, Hungary

Semmelweis University

semmelweis.hu
Budapest, Hungary

Founded in 1769, Semmelweis University is the oldest medical school in Hungary. The faculty became an independent medical school after the Second World War and developed into a university teaching medicine, dentistry, pharmacy, health science, and health management, as well as physical education and sport science. The university is named after Ignác Semmelweis , the obstetrician who discovered the cause of puerperal fever in the 1840s.The university has around 10,000 students from 60 nations over five continents. Its five faculties offer courses from undergraduate to doctorate level in Hungarian, English, and German. Foreign students account for about 18% of the total community.Semmelweis University is the largest health care institution in Hungary, with over 9,000 employees covering about 6% of the health care needs of the country’s population.With a quarter of a million of books, Semmelweis University has one of the biggest and best-furnished medical-biological collections in Hungary, and among the Hungarian universities, Semmelweis produces the greatest number of publications. The university is deeply involved in the patient care of the Great-Budapest region. Of its 3000 clinical beds, 75% take part in the regional medical care and some special outpatients' departments also supply the teaching hospitals with patients needed for the training.The portrait of Maria Theresa in the Assembly Hall of the University still commemorates the founding of the Medical Faculty by the Empress of Austria-Hungary more than 230 years ago, forging a continuous link in the education and training of medical students.The name of the University honors Ignác Semmelweis, a former professor of the Medical Faculty between 1855 and 1865, who discovered the cause and prevention of puerperal fever. Semmelweis was the first Hungarian university, which started to offer international courses at the Faculty of Medicine in German in 1983. The English programs started four years later, in 1987. Nowadays, the university enrolls more than 200 new international students each year. Still, students from Germany form the majority of the international student body, although numbers from Israel, Scandinavia, Ireland and Cyprus show consistent growth in recent years.The General Medicine program is listed by the WHO and it is recognized without any licensing examinations in all European Union countries The program leading to the Doctor of Medicine degree consists of six years: two years of general medical studies, three years of clinical studies, and one year of a rotating internship. International students enrolled in the English program are mostly from the EU, Norway, Israel, Cyprus, Iran, Japan, and the USA.The Semmelweis University seeks motivated candidates for the program with a solid background in biology and chemistry. In addition to these subjects, students must pass an entrance exam in English. The application deadline is in April and the course starts in September. Entrance exams are arranged at several locations in Europe, Israel, North America, Asia, and Africa.Since 1 September 2014, the Faculty of Physical Education and Sport science has been separated from Semmelweis University and continues to operate as an independent institution under the name University of Physical Education. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Wayne State University, Semmelweis University, Office of Technology Transfer and Genesis Theranostix Korlatolt Felelossegu Tarsasag | Date: 2017-06-21

Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.


Chinopoulos C.,Semmelweis University
Journal of Neuroscience Research | Year: 2013

The citric acid cycle forms a major metabolic hub and as such it is involved in many disease states involving energetic imbalance. In spite of the fact that it is being branded as a "cycle", during hypoxia, when the electron transport chain does not oxidize reducing equivalents, segments of this metabolic pathway remain operational but exhibit opposing directionalities. This serves the purpose of harnessing high-energy phosphates through matrix substrate-level phosphorylation in the absence of oxidative phosphorylation. In this Mini-Review, these segments are appraised, pointing to the critical importance of the α-ketoglutarate dehydrogenase complex dictating their directionalities. © 2013 Wiley Periodicals, Inc.


Gonda X.,Semmelweis University
Current Pharmaceutical Design | Year: 2012

NMDA receptors are ionotropic receptors mediating glutamatergic neurotransmission and play a role in several basic functions in the central nervous system, from regulating neurodevelopment and synaptic plasticity, learning and memory formation, cognitive processes, rhythm generation necessary for locomotor activity and breathing, and excitotoxicity. Due to their complex involvement in the above processes, NMDA receptors have been established to play a role in the etiopathology of several neuropsychiatric disorders such as ischaemia and traumatic brain injury, neurodegenerative disorders, pain syndromes, addiction, affective disorders and such neurodevelopmental disorders as autism or schizophrenia. NMDA receptors contain multiple types of subunits with distinct functional and pharmacological properties making the picture more complex. These receptors also offer multiple binding sites to be targeted with pharmacons, however, early broad-spectrum NMDA receptor antagonists had limited clinical use due to their intolerable adverse effect profile. The discovery of several types of subunit selective NMDA receptor antagonists may offer valuable therapeutic possibilities for several disorders, with improved clinical efficacy and decreased side effects. However, in spite of our increasing knowledge concerning the involvement of NMDA receptors in pathological processes, molecules with a selective action, tolerable side effect profile and good clinical efficacy are still only in clinical development in the majority of cases. Nevertheless, NMDA receptors offer a novel opportunity in the treatment of various neuropsychiatric conditions. © 2012 Bentham Science Publishers.


Grant
Agency: European Commission | Branch: H2020 | Program: ERC-STG | Phase: ERC-StG-2015 | Award Amount: 1.02M | Year: 2016

Imagine if tumor growth would be reduced and then kept in a minimal and safe volume in an automated manner and in a personalized way, i.e. cancer drug would be injected using a continuous therapy improving the patients quality of life. By control engineering approaches it is possible to create model-based strategies for health problems. Artificial pancreas is an adequate example for this, where by continuous glucose measurement device and insulin pump it is possible to improve diabetes treatment. Gaining expertise from this problem, the current proposal focuses on taming the cancer by developing an engineering-based medical therapy. The interdisciplinary approach focuses on modern robust control algorithm development in order to stop the angiogenesis process (i.e. vascular system development) of the tumor; hence, to stop tumor growth, maintaining it in a minimal, tamed form. This breakthrough concept could revitalize cancer treatment. It is the right time to do it as some investigations regarding tumor growth modeling have been already done; now, it should be refined by model identification tools and validated on animal trials. The benefit of robust control was already demonstrated in artificial pancreas; hence, it could be adapted to cancer research. The result could end with a personalized healthcare approach for drug-delivery in cancer, improving quality of life, optimizing drug infusion and minimizing treatment costs. This interdisciplinary approach combines control engineering with mathematics, computer science and medical sciences. As a result, the model-based robust control approach envisage refining the currently existing tumor growth modeling aspects, design an optimal control algorithm and extend it by robust control theory to guarantee its general applicability. Based on our research background, validation will be done first in a manually controlled way, but then in an automatic mode to propose it for further human investigations.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-23-2014 | Award Amount: 5.99M | Year: 2015

ADVOCATE brings together top principal investigators from prestigious universities, the public sector, and the private sector to address the most common diseases affecting humanity, as measured by the recent Global Burden of Disease Study. ADVOCATE strives to optimise delivery of oral health and wellbeing to the population in EU Member States. This requires a change in oral health care delivery towards prevention. The change will be achieved by developing a model that promotes a preventive rather than restorative oral health care system: The oral health care model 2020. As the oral health care delivery system is not as overly complex as other health care systems, the oral health care model 2020 may serve as a blueprint for other health care system reforms. The development of this model requires intensive information exchange and engagement of stakeholders to establish a set of key-indicators. These indicators will be used to benchmark health care performance on practice as well as system level. Two types of evidence-based indicators will be selected: Quantitative and qualitative indicators that allow measuring and influencing of either intrinsic motivation or extrinsic motivation incentives towards a patient centred, resilient and prevention oriented oral health care system. ADVOCATE will test this model in a natural environment, and provide evidence-informed policy measures towards its implementation, both for oral health care systems as well as other health care systems. Given the comprehensiveness of the topic, ADVOCATE uses a targeted approach that is entirely focused on the five major root-causes underlying the current suboptimal performance of oral health care systems. Moreover, ADVOCATE has confirmed access to data of eight European oral health care databases; it is well connected to existing initiatives and networks, and has ample support from preventive oriented industry, as exemplified by the financial support provided for the final conference.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.77M | Year: 2015

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population ( 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-2 | Award Amount: 7.70M | Year: 2014

Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test for CAD currently available. CT may become the most effective strategy to reduce the ca. 2 million annual negative ICAs in Europe by enabling early and safe discharge of the majority of patients with an intermediate risk of CAD. To evaluate this, we propose the DISCHARGE project that will be implemented by a multinational European consortium. The core of the project is the DISCHARGE pragmatic randomised controlled trial. The primary hypothesis will be that CT is superior to ICA for major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) after a maximum follow-up of 4 years in a selected broad population of stable chest pain patients with intermediate pretest likelihood of CAD. The trial will include 23 clinical sites from 18 European countries ensuring broad geographical representation. Comparative effectiveness research of complementing work packages include gender-related analysis, systematic review of evidence, cost-effectiveness analysis, and health-related quality of life. DISCHARGE has the capability to influence current standards and guidelines as well as coverage decisions and will raise awareness among patients, health care providers, and decision-makers in Europe about the effectiveness and cost-effectiveness of coronary CT angiography.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-26-2014 | Award Amount: 4.03M | Year: 2015

In European Union approximately 5 million people suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant. These patients present persistent positive symptomatology, require extensive periods of hospital care, and have a greater risk of excess mortality and multi-morbidity. In addition, a high proportion of the total cost for treating schizophrenia is spent on this population (Kennedy et al., 2013). Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Evidence from studies point to the importance of engaging patients actively in their own treatment. This active role helps to improve adherence to treatment, and to reduce persistent symptoms severity, relapses and hospitalizations (Mueser et al., 2002). m-RESIST aims to develop an intervention programme based on mHealth to allow patients suffering from resistant schizophrenia to self-manage their condition (resistant schizophrenia and its associated comorbidities, e.g. somatic disorders and addictions). This may facilitate acceptance and involvement of patients with their own treatment, as well as of caregivers. Moreover this programme could provide a new tool to the psychiatrist, psychologists working together with other health care professionals, to better monitor patients, through a personalised and optimised therapeutic process. m-resist will (1) develop and validate an mHealth solution aimed to reduce the severity of episodes and further complications; (2) involve and promote participation of patients and caregivers in the therapeutic process increasing the awareness of patient and caregiver about the nature of the illness and its consequences, benefits of treatment and needs for healthy habits and promoting an active and collaborative role with the medical team in the treatment decision-making procedure.

Loading Semmelweis University collaborators
Loading Semmelweis University collaborators